<DOC>
	<DOCNO>NCT00009841</DOCNO>
	<brief_summary>RATIONALE : Gene therapy may kill cancer cell inhibit gene promotes development growth cancer . PURPOSE : Phase I trial study effectiveness gene therapy treat patient advanced head neck cancer .</brief_summary>
	<brief_title>Gene Therapy Treating Patients With Advanced Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety biological activity EGFR antisense DNA DC-chol liposomes patient advance squamous cell carcinoma head neck . II . Determine toxicity maximum tolerate dose regimen patient . III . Determine antitumor response patient treat regimen . IV . Determine effect regimen EGFR expression level , STAT protein expression/activation level , apoptosis rate biopsied tumor cell patient . OUTLINE : This dose-escalation study . Patients receive EGFR antisense DNA DC-chol liposomes intratumorally weekly 4 week . Courses repeat every 4 week 6 month absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos EGFR antisense DNA DC-chol liposomes maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose-limiting toxicity . Patients follow 1 month . PROJECTED ACCRUAL : A total 20-36 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced squamous cell carcinoma head neck Primary recurrent disease Not amenable standard therapy ( surgery , chemotherapy , radiotherapy ) Second primary lesion allow Brain metastasis allow definitive radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL SGOT great 4 time normal Renal : Creatinine great 2 mg/dL Calcium great 10.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ( doublebarrier method oral contraception ) prior , , least 2 week study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>